Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization

Oncotarget
Cheng-Shi ChenHai-Liang Li

Abstract

This study evaluated the factors impacting overall survival (OS) and time to progression (TTP) in patients with unresectable hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE). HCC patients were grouped based on tumor vascularity and lipidiol deposition after TACE. Tumor vascularity was classified based on contrast enhancement on arterial phase baseline CT scans. Lipiodol deposition was evaluated using CT scans. The progression-free rate was significantly higher in patients with good blood supply + good lipiodol deposition compared to those with good blood supply + poor lipiodol deposition. In patients with poor lipidiol deposition, risk of death was significantly positively correlated with stage, and negatively correlated with number of TACE procedures and degree of lipidiol deposition after the first TACE. Risk of disease progression in these patients was positively correlated with tumor size, and negatively correlated with number of TACE procedures and degree of lipidiol deposition after the first TACE. Our data showed that tumor vascularity and lipiodol deposition can be used as early radiological markers to identify patients who do not respond to TACE, and who can be considered earlier for a...Continue Reading

References

Mar 17, 1999·Annals of Surgery·S T FanJ Wong
Mar 16, 2002·Journal of Gastroenterology and Hepatology·Jae Kyun LeeDong Jin Suh
Dec 12, 2003·Lancet·Josep M LlovetJordi Bruix
Jun 29, 2004·World Journal of Gastroenterology : WJG·Zhen LiYan-Rong Huang
Oct 28, 2004·Gastroenterology·Jordi BruixJosep M Llovet
Feb 17, 2005·Journal of the National Cancer Institute·Ming-Whei YuChien-Jen Chen
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Jan 8, 2008·The American Journal of Gastroenterology·Adriana SergioFabio Farinati
Feb 23, 2010·Seminars in Liver Disease·Alejandro FornerJordi Bruix
Jun 22, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Riccardo Lencioni
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Jun 20, 2014·World Journal of Gastroenterology : WJG·Woo Sun RouHeon Young Lee
Mar 6, 2015·National Science Review·Pengyuan YangXiao-Fan Wang
Jul 25, 2015·World Journal of Hepatology·Maria TampakiJohn Koskinas

❮ Previous
Next ❯

Citations

Dec 31, 2016·Oncotarget·Jun-Hui SunShu-Sen Zheng
Jan 23, 2019·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Lihui HuangHui Zhu
Oct 5, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lynn Jeanette SavicJulius Chapiro
Jan 23, 2021·Cancer Biotherapy & Radiopharmaceuticals·Marcel C LangenbachTatjana Gruber-Rouh
Jun 14, 2021·Abdominal Radiology·Marielia GerenaAnia Kielar

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

SPSS

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.